Chibueze D. Nwagwu

Chibueze D. Nwagwu

Auto-generated profile, based on publicly available information

Chibueze D. Nwagwu

Department of Neurosurgery, Brigham and Women’s Hospital, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SMSneha Sai Mannam
Sneha Sai Mannam
DBDavid P Bray
David P Bray
CNChibueze D. Nwagwu
Chibueze D. Nwagwu
Jim ZhongJim Zhong
Jim Zhong
Hui-Kuo George ShuHui-Kuo George Shu
Hui-Kuo George Shu
KHKimberly B. Bojanowski Hoang
Kimberly B. Bojanowski Hoang
In the context of the post-genomic era, where targeted oncological therapies like monoclonal antibodies (mAbs) and tyrosine-kinase inhibitors (TKIs) are gaining prominence, this study investigates whether these therapies can enhance survival for lung carcinoma patients with specific genetic mutations—EGFR-amplified and ALK-rearranged mutations. Prior to this study, no research series had explored how these mutations influence patient survival in cases of surgical lung brain metastases (BMs). Through a multi-site retrospective analysis, the study examined patients who underwent surgical resection for BM arising from primary lung cancer at Emory University Hospital from January 2012 to May 2022. The mutational statuses were determined from brain tissue biopsies, and survival analyses were conducted. Results from 95 patients (average age: 65.8 ± 10.6) showed that while 6.3% had anaplastic lymphoma kinase (ALK)-rearranged mutations and 20.0% had epidermal growth factor receptor (EGFR)-amplified mutations—with 9.5% receiving second-line therapies—these mutations did not significantly correlate with overall survival. Although the sample size of patients receiving targeted therapies was limited, the study highlighted improved overall survival and progression-free survival rates compared to earlier trials, suggesting advancements in systemic lung metastasis treatment. The study suggests that as more targeted therapies emerge, the prospects for increased overall survival and progression-free survival in lung brain metastasis patients will likely improve.